Skip to content
Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Get the podcast

Anton Hagenbeek ANTON HAGENBEEK, University Medical Centre Utrecht For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free surv

The Audio Journal of Oncology
Anton Hagenbeek

Anton Hagenbeek

ANTON HAGENBEEK, University Medical Centre UtrechtFor patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study authorAnton Hagenbeekat the ASH meeting in Atlanta whileGeorge Canellosprovided comment.

LISTEN

Tags

ashcommentslymphomamedicalmedicationpatientpodcastpodcastingreportreportsstudytoxicity

Next in ASH 2007

All 11 interviews

Interview 4 of 11

Live Report from ASH:<br />Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Live Report from ASH:<br />Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Christian Geisler CHRISTIAN GEISLER, Rigshospitalet, Copenhagen Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek T

11 December 2007

Related Episodes

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

24 Jan 2020
3 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 Oct 2019
10 min
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia

Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

19 Dec 2013